Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion

European Journal of Clinical Investigation

Volumn 32, Issue SUPPL. 1, 2002, Pages 36-41

  Kooistra, M P ^a,b   Kersting, S ^a   Gosriwatana, I ^c   Lu, S ^c   Nijhoff Schutte, J ^a   Hider, R C ^c   Marx, J J M ^d  

^a Dianet Foundation   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Ferric saccharate; Haemodialysis; Iron; Nontransferrin bound iron

Indexed keywords

COBALT; HYDROXYL RADICAL; IRON; IRON BINDING PROTEIN; IRON SACCHARATE; NITRILOTRIACETIC ACID; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; DIALYSIS FLUID; FERRIC ION; FERRIC OXIDE, SACCHARATED; FERRITIN;

ANEMIA; ARTICLE; ATHEROSCLEROSIS; CATALYST; CELL DAMAGE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DIALYSATE LEVEL; DOSE TIME EFFECT RELATION; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON METABOLISM; KIDNEY FAILURE; PRIORITY JOURNAL; BLOOD; CHEMISTRY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; PROTEIN BINDING; RENAL REPLACEMENT THERAPY;

ANEMIA; DIALYSIS SOLUTIONS; FEMALE; FERRIC COMPOUNDS; FERRITINS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MALE; PROTEIN BINDING; RENAL DIALYSIS; TRANSFERRIN;

EID: 19044392916     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.0320s1036.x     Document Type: Article

References (22)

1. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;ii:1175-8.
2. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987;316:73-8.
3. Kühn K, Nonnast-Daniel B, Grützmacher P, Grüner J, Pfäffl W, Baldamus CA, et al. Analysis of initial resistance of erythropoiesis to treatment with recombinant human erythropoietin. Results of a multicenter trial in patients with end-stage renal disease. Contrib Nephrol 1988;66:94-103.
4. Macdougall IC. Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 1995;10:607-14.
5. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 1989;35:712-6.
6. Kooistra MP, van Es A, Struyvenberg A, Marx JJM. Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 1991;79:634-9.
7. Hörl WH, Cavill I, Macdougall IC, Schaefer RM, Sunder-Plasmann G. How to diagnose and correct iron deficiency during r-huEPO therapy - a consensus report. Nephrol Dial Transplant 1996;11:246-50.
8. Drücke TB, Bárány P, Cazzola M, Eschbach JW, Grützmacher P, Kaltwasser JP, et al. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin- treated patients. Clin Nephrol 1997;1:1-8.
9. Macdougall IC, David Hutton R, Cavill I, Coles GA, Williams JD. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br Med J 1989;299:157-8.
10. Sünder-Plasmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995;10:2070-6.
11. Taylor JE, Peat N, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1996;11:1079-83.
12. Zanen AL, Adriaansen HJ, Bommel EFH, Posthuma R, de Jong GMTh. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant 1996;11:820-4.
13. Sünder-Plasmann G, Hörl WH. Safety of intravenous injection of iron saccharate in heamodialysis patients. Nephrol Dial Transplant 1996;11:1797-802.
14. Gutteridge JMC, Halliwell B. Iron and oxygen: a dangerous mixture. In: Ponka P, Schulman HM, Woodworth RC, editors. Iron Transport and Storage. Boca Raton, FL: CRC Press; 1990, pp. 55-65.
15. Marx JJM, van Asbeck BS. Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Acta Haematol 1996;95:49-62.
16. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transfemn-bound iron. Anal Biochem 1990;186:320-3.
17. Gosriwatana I, Loreal O, Lu S, Brissot P, Hider RC. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem 1999;273:212-20.
18. Makey DG, Seal UA. The detection of four molecular forms of human transferrin during the iron binding process. Biochim Biophys Acta 1976;453:250-6.
19. De Valk B, Addicks MA, Gosriwatana I, Lu S, Hider RC, Marx JJM. Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. Eur J Clin Invest 2000;30:248-51.
20. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-5.
21. Loréal O, Gosriwatana I, Guyader D, Porter J, Brissot P, Hider RC. Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. J Hepatol 2000;32:727-33.
22. Espósito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma non-transferrin-bound iron in dialysis patients. Eur J Clin Invest 2002;32 (Suppl 1):42-49.